Table 2 Overall response rates and liver resection rate

From: Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)

 

Overall response rates

P

 

mFOLFOX6+BEV

mFOLFOX6+CET

 

CR (%)

1 (1.8%)

1 (1.7%)

—

PR (%)

38 (66.7%)

49 (83.1%)

—

SD (%)

18 (31.6%)

6 (10.2%)

—

PD (%)

0 (0.0%)

2 (3.4%)

—

NE

0 (0.0%)

1 (1.7%)

—

Overall response rate

68.4%

84.7%

0.0483

Disease control rate

100%

94.9%

0.2437

 

Liver resection rate

 

mFOLFOX6+BEV

mFOLFOX6+CET

R0+R1

28 (49.1%)

28 (47.5%)

R0

25 (43.9%)

22 (37.3%)

R1

3 (5.3%)

6 (10.2%)

R2

4 (7.0%)

1 (1.7%)

All

32 (56.1%)

29 (49.2%)

Reasons for R2

Ablation: 2

Ablation and Residual: 1

 

Residual: 2

  1. BEV bevacizumab, CET cetuximab, CR complete response, mFOLFOX6 5-fluorouracil/folinic acid, oxaliplatin, NE not evaluable, PD progressive disease, PR partial response, SD stable disease
Back to article page